View More Recent Stories
-
Medicus Pharma (MDCX) Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BC
-
Medicus Pharma (MDCX) Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange
-
Brookline Capital Markets Starts Medicus Pharma Ltd. (MDCX) at Buy
-
Medicus Pharma (MDCX) Announces FDA Minor Use Designation for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
-
Medicus Pharma (MDCX) Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
-
Medicus Pharma (MDCX) Appoints Faisal Mehmud as Chief Medical Officer
-
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
-
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
